DNA损伤
PARP抑制剂
聚ADP核糖聚合酶
癌症研究
DNA修复
生物
DNA
癌症
分子生物学
遗传学
化学
聚合酶
作者
Antao Chang,Liang Liu,Justin M. Ashby,Dan Wu,Yanan Chen,Stacey S. O’Neill,Shan Huang,Juan Wang,Guanwen Wang,Dongmei Cheng,Xiaoming Tan,W. Petty,Boris Pasche,Rong Xiang,Wei Zhang,Peiqing Sun
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2021-04-14
卷期号:81 (12): 3358-3373
被引量:66
标识
DOI:10.1158/0008-5472.can-21-0688
摘要
Abstract When recruited to promoters, histone 3 lysine 4 (H3K4) methyltransferases KMT2 (KMT2A-D) activate transcription by opening chromatin through H3K4 methylation. Here, we report that KMT2 mutations occur frequently in non–small cell lung cancer (NSCLC) and are associated with high mutation loads and poor survival. KMT2C regulated DNA damage responses (DDR) through direct recruitment to DNA damage sites by Ago2 and small noncoding DNA damage response RNA, where it mediates H3K4 methylation, chromatin relaxation, secondary recruitment of DDR factors, and amplification of DDR signals along chromatin. Furthermore, by disrupting homologous recombination (HR)–mediated DNA repair, KMT2C/D mutations sensitized NSCLC to Poly(ADP-ribose) polymerase inhibitors (PARPi), whose efficacy is unclear in NSCLC due to low BRCA1/2 mutation rates. These results demonstrate a novel, transcription-independent role of KMT2C in DDR and identify high-frequency KMT2C/D mutations as much-needed biomarkers for PARPi therapies in NSCLC and other cancers with infrequent BRCA1/2 mutations. Significance: This study uncovers a critical role for KMT2C in DDR via direct recruitment to DNA damage sites, identifying high-frequency KMT2C/D mutations as biomarkers for response to PARP inhibition in cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI